论文部分内容阅读
目的研究用乙酰胆碱受体α亚基97-116肽段制作实验性重症肌无力(EAMG)的动物模型。方法给实验组Lewis鼠皮下注射人工合成的鼠源性乙酰胆碱受体α亚基97-116肽段,观察接种后大鼠一般情况及体重、Lennon评分变化,应用低频重复电刺激检测电衰减反应,并与对照组鼠比较。结果模型组大鼠在第1次强化免疫后逐渐出现肌无力症状,体重增长缓慢或下降,甚至消瘦,毛发变得暗淡、粗糙甚至脱落,再次加强免疫后上述症状明显加重。Lennon临床评分29只评分在1级以上,并行RNS检测,36只模型鼠中32只5 Hz重复刺激电衰减率>10%,而对照组衰减率均<10%,两组比较差异有显著性(P<0.01)。结论皮下注射鼠源性乙酰胆碱受体α亚基97-116肽段可成功制作实验性自身免疫性重症肌无力大鼠模型。
Objective To study the experimental animal model of experimental myasthenia gravis (EAMG) using the acetylcholine receptor α subunit 97-116 peptide. Methods The experimental group rats were subcutaneously injected with the 97-116 α subunit of murine acetylcholine receptor, and the changes of general and weight, Lennon score were observed. The electrical decay reaction was detected by low frequency repeated electrical stimulation. Compared with the control group rats. Results The rats in the model group developed symptoms of myasthenia gravis gradually after the first immunization, the weight gain was slow or even decreased, and the hair became dull, rough or even exfoliated. The above symptoms were obviously aggravated again after the immunization. Lennon’s clinical score of 29 was higher than level 1 in parallel with RNS test, 32 of 5, 5 Hz repetitive stimulus decay rate of 36 rats was> 10%, while the decay rate of control group was <10%, the difference was significant (P <0.01). Conclusion The experimental autoimmune myasthenia gravis model can be successfully established by subcutaneous injection of the murine acetylcholine receptor α subunit 97-116 peptide.